---
title: "DBK: Record H1 profit, strong capital, and robust segment performance support 2026 targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294330177.md"
description: "Record H1 profit and strong revenue growth were driven by all divisions achieving ROTE of 12% or higher, with CET1 at 13.9% and a €500m buyback approved. Portfolio quality remains robust, and the bank is on track for its FY 2026 and 2028 targets.Original document: Deutsche Bank Aktiengesellschaft [DBK] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T08:49:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294330177.md)
  - [en](https://longbridge.com/en/news/294330177.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294330177.md)
generator: "portal-rs"
---

# DBK: Record H1 profit, strong capital, and robust segment performance support 2026 targets

Record H1 profit and strong revenue growth were driven by all divisions achieving ROTE of 12% or higher, with CET1 at 13.9% and a €500m buyback approved. Portfolio quality remains robust, and the bank is on track for its FY 2026 and 2028 targets.

Original document: Deutsche Bank Aktiengesellschaft \[DBK\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [Deutsche Bank freed from consent order in 2010s FX scandal](https://longbridge.com/en/news/296541279.md)
- [DBK: Record H1 profit, strong revenue growth, and robust capital position drive positive outlook](https://longbridge.com/en/news/294154843.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**